Table 2.
Pathological stage, neoadjuvant therapy receipt, surgical technique in patients who underwent esophagectomy for malignancy in the American College of Surgeons National Surgical Quality Improvement Program database from January 2005 through December 2020
| Variable | Total | Non-emergent esophagectomy | Emergent esophagectomy |
|---|---|---|---|
| No. of patients | 10,067 | 9,886 | 181 |
| Clinical stagea) | |||
| Stage 0 | 29 (1.22) | 29 (1.23) | 0 |
| Stage I | 288 (12.11) | 286 (12.14) | 2 (8.33) |
| Stage II | 375 (15.76) | 373 (15.84) | 2 (8.33) |
| Stage III | 1,344 (56.49) | 1,327 (56.35) | 17 (70.83) |
| Stage IV | 343 (14.42) | 340 (14.44) | 3 (12.50) |
| Neoadjuvant therapya),b) | |||
| Neoadjuvant chemotherapy | 319 (17.84) | 310 (17.84) | 9 (16.67) |
| Neoadjuvant radiation | 606 (33.97) | 587 (33.93) | 19 (35.19) |
| Hospital admission to operation (day) | 0±5.37 | 0.237±5.36 | 2.43±5.77 |
| Surgical specialty | |||
| Thoracic surgery | 4,353 (43.24) | 4,284 (43.33) | 69 (38.12) |
| General surgery | 5,607 (55.70) | 5,499 (55.62) | 108 (59.67) |
| Others | 107 (1.06) | 103 (1.04) | 4 (2.21) |
| Surgical technique | |||
| Ivor Lewis | 5,394 (53.58) | 5,319 (53.80) | 75 (41.44) |
| McKeown | 1,730 (17.18) | 1,697 (17.17) | 33 (18.23) |
| Transhiatal | 2,755 (27.37) | 2,689 (27.20) | 66 (36.46) |
| No reconstruction | 163 (1.62) | 158 (1.60) | 5 (2.76) |
| Total operative time (min) | 349 (265–445) | 349 (266–445) | 334 (250–454) |
Values are presented as number, number (%) for categorical variables, mean±standard deviation, or median (25th–75th) for continuous variables.
a)Data reported for patients who underwent esophagectomy between 2016 and 2020 (2,866 patients). b)Neoadjuvant therapy within 90 days before surgery.